Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer

被引:52
|
作者
Cron, Kyle R. [1 ]
Zhu, Kaya [1 ]
Kushwaha, Deepa S. [1 ]
Hsieh, Grace [1 ]
Merzon, Dmitry [1 ]
Rameseder, Jonathan [2 ]
Chen, Clark C. [3 ]
D'Andrea, Alan D. [1 ,4 ]
Kozono, David [1 ]
机构
[1] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[2] MIT, Cambridge, MA 02139 USA
[3] Univ Calif San Diego, Div Neurosurg, San Diego, CA 92103 USA
[4] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
来源
PLOS ONE | 2013年 / 8卷 / 09期
基金
美国国家卫生研究院;
关键词
NF-KAPPA-B; DOUBLE-STRAND BREAKS; MULTIPLE-MYELOMA; MAMMALIAN-CELLS; GENE-EXPRESSION; SOLID TUMORS; BORTEZOMIB; ADENOCARCINOMA; RECOMBINATION; CHEMOTHERAPY;
D O I
10.1371/journal.pone.0073710
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Despite optimal radiation therapy (RT), chemotherapy and/or surgery, a majority of patients with locally advanced non-small cell lung cancer (NSCLC) fail treatment. To identify novel gene targets for improved tumor control, we performed whole genome RNAi screens to identify knockdowns that most reproducibly increase NSCLC cytotoxicity. These screens identified several proteasome subunits among top hits, including the topmost hit PSMA1, a component of the core 20 S proteasome. Radiation and proteasome inhibition showed synergistic effects. Proteasome inhibition resulted in an 80-90% decrease in homologous recombination (HR), a 50% decrease in expression of NF-kappa B-inducible HR genes BRCA1 and FANCD2, and a reduction of BRCA1, FANCD2 and RAD51 ionizing radiation-induced foci. I kappa B alpha RNAi knockdown rescued NSCLC radioresistance. Irradiation of mice with NCI-H460 xenografts after inducible PSMA1 shRNA knockdown markedly increased murine survival compared to either treatment alone. Proteasome inhibition is a promising strategy for NSCLC radiosensitization via inhibition of NF-kappa B-mediated expression of Fanconi Anemia/HR DNA repair genes.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] DNA repair pathways and non-small cell lung cancer: clinical perspectives
    Olaussen, Ken Andre
    Planchard, David
    Adam, Julien
    Soria, Jean-Charles
    BULLETIN DU CANCER, 2011, 98 (03) : 305 - 321
  • [2] BRAF Inhibitors in Non-Small Cell Lung Cancer
    Sforza, Vincenzo
    Palumbo, Giuliano
    Cascetta, Priscilla
    Carillio, Guido
    Manzo, Anna
    Montanino, Agnese
    Sandomenico, Claudia
    Costanzo, Raffaele
    Esposito, Giovanna
    Laudato, Francesca
    Damiano, Simona
    Forte, Cira Antonietta
    Frosini, Giulia
    Farese, Stefano
    Piccirillo, Maria Carmela
    Pascarella, Giacomo
    Normanno, Nicola
    Morabito, Alessandro
    CANCERS, 2022, 14 (19)
  • [3] Emerging angiogenesis inhibitors for non-small cell lung cancer
    Malapelle, Umberto
    Rossi, Antonio
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (02) : 71 - 81
  • [4] RAF and MEK Inhibitors in Non-Small Cell Lung Cancer
    Adamopoulos, Christos
    Papavassiliou, Kostas A.
    Poulikakos, Poulikos I.
    Papavassiliou, Athanasios G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (09)
  • [5] Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
    Wang, Shuai
    Hao, Jiatao
    Wang, Hao
    Fang, Yong
    Tan, Lijie
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [6] Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung
    Giaccone, G
    vanArkOtte, J
    Scagliotti, G
    Capranico, G
    vanderValk, P
    Rubio, G
    Dalesio, O
    Lopez, R
    Zunino, F
    Walboomers, J
    Pinedo, HM
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1995, 1264 (03): : 337 - 346
  • [7] BRAF inhibitors in metastatic non-small cell lung cancer
    Anguera, Georgia
    Majem, Margarita
    JOURNAL OF THORACIC DISEASE, 2018, 10 (02) : 589 - 592
  • [8] Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells
    Li, Yanhui
    Dong, Su
    Tamaskar, Arya
    Wang, Heather
    Zhao, Jing
    Ma, Haichun
    Zhao, Yutong
    ONCOLOGY RESEARCH, 2020, 28 (05) : 497 - 507
  • [9] The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer
    Galetta, Domenico
    Rossi, Antonio
    Pisconti, Salvatore
    Colucci, Giuseppe
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 : S45 - S54
  • [10] BRAF inhibitors in advanced BRAF-positive non-small cell lung cancer
    Vavala, Tiziana
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1323 - S1327